subscribeSubscribe
FDA Confirms Paragraph IV Patent Litigation for Beclomethasone Dipropionate Inhalation Aerosol

FDA Confirms Paragraph IV Patent Litigation for Beclomethasone Dipropionate Inhalation Aerosol
FDA
10 Jan 2024
Share Share
Lupin Healthcare launches Beclu carbon neutral inhalers for asthma treatment

Lupin Healthcare launches Beclu carbon neutral inhalers for asthma treatment
PHARMAFILE
22 Jun 2023
Share Share
NHS Scotland recommends Chiesi’s Trimbow for asthma

NHS Scotland recommends Chiesi’s Trimbow for asthma
PHARMAFILE
18 Aug 2022
Share Share
Pts Packers And Providers is on FDA Import Alert List

Pts Packers And Providers is on FDA Import Alert List
FDA
19 Jul 2021
Share Share
FDA Confirms Paragraph IV Patent Challenge of Qvar 20911 (Beclomethasone Dipropionate) 40 mcg/actuation and 80 mcg/actuation

FDA Confirms Paragraph IV Patent Challenge of Qvar 20911 (Beclomethasone Dipropionate) 40 mcg/actuation and 80 mcg/actuation
FDA
29 Feb 2020
Share Share
Class 3 FMD Medicines Recall

Class 3 FMD Medicines Recall
PSNC
12 Feb 2020
Share Share
NPPA fixes retail prices of 22 formulations under DPCO, 2013

NPPA fixes retail prices of 22 formulations under DPCO, 2013
PHARMABIZ
06 May 2019
Share Share
Determination That QVAR 40 and QVAR 80 Beclomethasone Dipropionate HFA

Determination That QVAR 40 and QVAR 80 Beclomethasone Dipropionate HFA
FEDERALREGISTER
04 Apr 2019
Share Share
Chiesi Farmaceutici`s Riarify (beclometasone;formoterol;glycopyrronium bromide) Receives Approval In Europe

Chiesi Farmaceutici`s Riarify (beclometasone;formoterol;glycopyrronium bromide) Receives Approval In Europe
EMA
27 Apr 2018
Share Share
Five new medicines backed for EU approval

Five new medicines backed for EU approval
Selina McKee PHARMA TIMES
26 Feb 2018
Share Share